HTHenrik Holm Thomsen

Henrik Holm Thomsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henrik Holm Thomsen has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dynamic Responses to an Inflammatory Challenge Distinguish Metabolic Health Across Lean and Obese Individuals

    by Saeideh Tavajoh, Bianca E. Suur, Madison Clark, Adriana A. Becerril-Campos, Elia Velasco, Brigita Medelytė, Line Boel Nørregaard, Stine Julie Tingskov, Amanda Bæk, Lykke Skaarup, et al.

    Summary: Inflammation is a key driver of cardiometabolic disease, yet it remains unclear whether systemic inflammatory markers can distinguish metabolically healthy from unhealthy individuals or capture the temporal dynamics of inflammation. Here, we combined systemic immune profiling with a cantharidin-induced peripheral blister model to investigate dynamic inflammatory regulation across metabolic phenotypes in metabolically healthy lean (MHL), metabolically unhealthy lean (MUL), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO) individuals. While systemic inflammation was elevated in obesity, differences between metabolically healthy and unhealthy groups were modest, with limited discrimination by plasma proteomics, circulating leukocyte phenotyping, and whole-blood transcriptomics. In contrast, the dynamic response to inflammatory challenge revealed pronounced differences at proteomic, cellular, and transcriptomic levels. Metabolically unhealthy individuals exhibited exaggerated early innate immune responses, impaired inflammatory resolution and tissue repair, reduced recruitment of reparative immune cells, and sustained T cell presence. Transcriptomic analyses further showed blunted dynamic gene regulation and defective epidermal barrier restoration. These findings indicate that metabolic health is better reflected in tissue-level inflammatory dynamics than in systemic measures.

  • Open Access

    Faecal microbiota transplantation for improving insulin sensitivity in adults with type 2 diabetes mellitus (FeMIC): study protocol for a randomised controlled trial (Preprint)

    by Nanna Kold Rikhof, Ermina Bach, Maja Skov Kragsnaes, Susan Mikkelsen, Christian Erikstrup, Simon Mark Dahl Baunwall, Christian Lodberg Hvas, Henrik Holm Thomsen

    BACKGROUND Alterations in gut microbiota composition have been implicated in the pathogenesis of type 2 diabetes (T2DM), and faecal microbiota transplantation (FMT) has emerged as a microbiota-targeted intervention with potential metabolic effects. Randomised controlled trials evaluating the effects of FMT on insulin sensitivity in individuals with T2DM are limited. OBJECTIVE This study aims to investigate the effects of FMT on insulin sensitivity and glycaemic control in individuals with T2DM. METHODS This is a single-center, randomised, double-blind, placebo-controlled trial. Sixteen participants with T2DM have been randomised in a 1:1 ratio to receive FMT from two healthy donors or a placebo intervention, administered in two predefined procedures using capsules. Assessments were performed at baseline and after the intervention period. The primary outcome is insulin sensitivity, assessed using the Matsuda index derived from a standardised oral glucose tolerance test (OGTT) after six weeks. Secondary outcomes include dynamic insulin sensitivity assessed by the oral glucose insulin sensitivity index and detailed glycaemic profiling using continuous glucose monitoring (time-in-range, glycaemic variability), alongside anthropometry, circulating metabolic and inflammatory biomarkers, and gut microbiota composition and functional capacity. Outcomes will be analysed using analysis of covariance, adjusting for baseline values, and will follow the intention-to-treat principle. RESULTS As of June 2026, all 16 participants have been enrolled and completed all patient visits. Laboratory analyses for the primary outcomes are in progress and therefore no results are currently available. CONCLUSIONS This randomised controlled trial will evaluate whether repeated FMT can improve insulin sensitivity in individuals with T2DM. The integration of dynamic OGTT-derived insulin sensitivity indices and continuous glucose monitoring–based glycaemic profiling enables a comprehensive assessment of glucose metabolism following microbiota modulation. CLINICALTRIAL ClinicalTrials.gov, study identifier NCT07375797, registered on 12 January 2026

  • Open Access

    Intermittent exogenous ketosis increases erythropoietin in healthy adults: A randomized, placebo‐controlled study with preliminary sex‐specific observations

    by Henrik Holm Thomsen, Birgitte Sandfeld‐Paulsen, Lise Nørkjær Bjerg, Jesper Nørgaard Bech

    Exogenous ketosis may stimulate erythropoietin (EPO), yet its impact on erythropoiesis, iron metabolism, and potential sex‐specific responses in humans remains unknown. We investigated these effects in healthy adults using oral β‐hydroxybutyrate ketone monoester (KE) to induce intermittent ketosis. Acute EPO responses to a single dose of KE were assessed in 16 healthy adults (pre‐post), followed by a 2‐week randomized study (KE twice daily vs. placebo). After 2 weeks, EPO levels with intermittent ketosis were approximately 30% higher (95% CI 6, 60), p = 0.01, an effect more evident in females (9.7 IU/L (95% CI 6.0, 13.5) vs. 6.4 IU/L (95% CI 4.0, 8.8), p = 0.008) than in males (10.7 IU/L (7.2, 14.2) vs. 9.6 IU/L (6.3, 12.9), p = 0.46). Ferritin was elevated in females with KE vs. placebo (42 μg/L vs. 16 μg/L, p < 0.001). Hemoglobin and red blood cell count were unaffected at 2 weeks. Over 2 weeks, intermittent exogenous ketosis was associated with a modest increase in erythropoietin levels, with a stronger signal in females. Although hemoglobin and red blood cell count did not change significantly, females showed higher ferritin levels and a trend toward increased hematocrit, suggesting subtle effects on erythropoietic stimulation and iron handling.

  • Top Cited Papers

    Defining the vascular niche of human adipose tissue across metabolic states

    by Ibrahim AlZaim, Mohamed N. Hassan, Maja Schröter, Luca Mannino, Katarina Dragicevic, Marie Balle Sjogaard, Joseph Festa, Lolita Dokshokova, Sophie Weinbrenner, Blanca Tardajos Ayllon, et al.

    Adipose tissue homeostasis depends on an intact vascular network that ensures adequate nutrient delivery and immune regulation. In obesity, vascular dysfunction, particularly within endothelial cells (ECs), contributes to inflammation and metabolic disease progression, yet the cellular organization of the human adipose vasculature remains poorly defined. Here we show, using single-cell RNA sequencing of nearly 70,000 vascular cells from human subcutaneous adipose tissue of 65 individuals, that the adipose vasculature is highly heterogeneous and consists of seven canonical EC subtypes. In addition, we identify a distinct population of ECs that display mixed endothelial, mesenchymal, adipocytic and immune transcriptional features. Computational analyses and whole-mount imaging support their presence and suggest that they emerge through endothelial-to-mesenchymal transition. Comparative analyses further reveal inflammatory and fibrotic vascular signatures in obesity and type 2 diabetes. Together, this atlas delineates the cellular complexity of the human adipose vasculature and highlights its contribution to metabolic disease.


  • Open Access

    Association of the Tilburg Frailty Indicator with mortality, readmission, and healthcare contacts in adult patients with multimorbidity

    by Thomas J. Hjelholt, Thomas Veedfald, Anne Frølich, Charlotte Appel, Henrik Holm Thomsen, Anders Prior, Anne Dorthe Bjerrum, Marianne Balsby, Anne Marie Schak Jensen, Lene Kongsgaard Nielsen

    Purpose: Frailty is closely related to multimorbidity and unfavorable outcomes. The Tilburg Frailty Indicator (TFI) is a self-reported assessment comprising 15 questions across three domains. We assessed whether the TFI predicts 180-day mortality, 30-day readmission and healthcare contacts among adults with multimorbidity across a broad age range. Methods: Single-center prospective cohort study including adults with multimorbidity. Follow-up was 180 days. Cox regression analyses estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for death and readmission. Poisson regression estimated incidence rate ratios (IRR) of any health care contact. Exposure was TFI as both a dichotomous and a 0-15 points integer variable. Analyses were adjusted for age and sex. Results: We included 471 participants, median age 70 years (IQR 60-76 years) with an average of 6.0 chronic diseases. In adjusted analyses, frailty (TFI score > 5) was associated with HR 4.6 (CI 2.2, 9.7) for death and HR 2.6 (CI 1.7, 4.1) for readmission. Frailty was associated with an IRR of 1.5 (CI 1.3, 1.7) of any health care contact. A one-point increase in TFI score conferred increments in relative estimates across all outcomes. Conclusions: Our findings extend prior TFI research from older community-dwelling cohorts to multimorbid adults across clinical settings; TFI was both dichotomously and point-by point associated with adverse outcomes. TFI is a self-reported tool that offers a practical and efficient alternative to traditional frailty scoring systems, requiring neither clinical metrics nor expert evaluation, reducing time and resource demands. TFI may be a relevant multidomain risk assessment tool for care pathways in multimorbidity.

  • Open Access

    Continuous Ketone Monitoring: Data From a Randomized Controlled Trial

    by Simon K Kjær, Lukas Ochsner Reynaud Ridder, Mads Svart, Nikolaj Rittig, Lise Nørkjær Bjerg, Birgitte Sandfeld-Paulsen, Henrik Holm Thomsen

    In our study, a commercially available continuous ketone monitoring device captured β-Hydroxybutyrate (BHB) dynamics during exogenous ketosis but revealed a gradual decline day-to-day BHB concentrations over 14 days in both ketone ester and placebo groups, likely reflecting sensor drift.


  • Open Access

    Continuous ketone monitoring: Data from a randomized controlled trial (Preprint)

    by Simon K. Kjær, Lukas Ochsner Reynaud Ridder, Mads Svart, Nikolaj Rittig, Lise Nørkjær Bjerg, Birgitte Sandfeld-Paulsen, Henrik Holm Thomsen

    UNSTRUCTURED Abstract (summarizing sentence) In our study, the Sibio KS1 CKM device captured β-Hydroxybutyrate (BHB) dynamics during exogenous ketosis but revealed a gradual decline day-to-day BHB concentrations over 14 days in both KE and PBO groups, likely reflecting sensor drift.

  • The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes—rationale and protocol of the prospective, randomized, open‐labelled multicentre study

    by Elisabeth B. Stougaard, Mads R. Andersen, Jonatan I. Bagger, Esben Søndergaard, Jakob A. Østergaard, Viktor R. Curovic, Frederik Persson, Thomas Almdal, Anne Sophie Mathiesen, Alin Andries, et al.

    Aims: Individuals with type 1 diabetes are at high risk of cardiovascular disease (CVD) and chronic kidney disease (CKD) even with optimal glycaemic control. The Steno 1 study will test a strategy of intensified care based on multifactorial intervention (MFI) including treatment with semaglutide, sotagliflozin and finerenone in high‐risk individuals with type 1 diabetes. We hypothesize that this strategy will reduce major adverse cardiovascular endpoints (MACE), hospitalization for heart failure (HHF), progression of CKD and mortality. Materials and Methods: The study is a prospective, cluster‐randomized, open study with blinded endpoint evaluation. We will enrol 2000 high‐risk individuals with type 1 diabetes of >10 years duration. All five Steno Diabetes Centres and 11 partner hospitals in Denmark will participate, with the addition of the Steno Diabetes Centres in Greenland and the Faroe Islands. Sites will be randomized either to receive guideline‐recommended standard‐of‐care, or to receive the MFI. Eligible individuals with type 1 diabetes (≥40 years of age with presence of either CKD, CVD, HF, obesity or a >10% 5‐year CVD risk determined by the Steno T1 Risk Engine) will be included. For the MFI group, the intervention will comprise more ambitious treatment targets for blood pressure and lipid levels, and in addition, participants will be allocated to semaglutide, sotagliflozin and/or finerenone based on phenotype. Results and conclusions: The Steno 1 study will determine whether MFI is superior to standard care with respect to MACE, HHF progression of CKD, and mortality in individuals with type 1 diabetes and high risk of CVD.


  • Evaluating agreement between separate capillary sampling sites and venous concentrations of β-hydroxybutyrate measured by a point-of-care device and liquid chromatography tandem mass spectrometry

    by Lise Nørkjær Bjerg, Henrik Holm Thomsen, Birgitte Sandfeld-Paulsen

    β-hydroxybutyrate (BHB) is recommended as a measure of ketosis and is often assessed by capillary samples on point-of-care (POC) meters. However, liquid chromatography tandem mass spectrometry (LC-MS/MS) is considered the gold standard for assessing venous samples. The POC device KetoSureTM is recommended only for capillary samples from finger pricks. So far, KetoSureTM has not been compared to LC-MS/MS just as it has not been evaluated if the sampling site influences the BHB concentration. Blood samples were collected from 16 healthy, fasting individuals before and after ingestion of ketone monoester. BHB concentrations were measured in capillary samples from the earlobe and fingertip, and in venous blood using KetoSureTM. Venous plasma samples were collected for BHB quantification using LC-MS/MS. No sign of significant difference between values of BHB measured from the two capillary sampling sites were found. Interestingly, significantly higher values of BHB were measured in capillary samples compared to venous samples reflecting a systematic proportional relationship. No systematic difference was observed in the measured BHB concentrations when comparing KetoSureTM and LC-MS/MS results: However, a significant mean bias of 32% reflects a skewness at very low BHB concentrations. In conclusion, capillary BHB concentration did not exhibit variation between the earlobe and fingertip. Conversely, a significant bias was observed between venous and capillary blood and between the POC and LC-MS/MS methods. It is recommended that caution be exercised if individual monitoring of BHB changes encompasses both capillary and venous sampling.


  • Open Access

    Clinical and Metabolic Characterization of Women With Gestational Diabetes Mellitus Within the First Year Postpartum

    by Laura Løftgaard Knudsen, Sine Knorr, Susanne Kastberg Prange, Charlotte Wolff, Helle Nørgaard, Anne Mette Torp, Lene Ring Madsen, Lene Mortensen, Henrik Holm Thomsen, Lars Peter Sørensen, et al.

    Context: Women with gestational diabetes mellitus (GDM) have an increased risk of long-term complications, including impaired glucose metabolism, type 2 diabetes (T2DM), cardiovascular disease, and obesity. In current clinical practice, a 1 size fits all approach to GDM is applied, although heterogeneity among women with GDM has been recognized. Objective: To give the most adequate preventive care and postpartum (PP) guidance, we aimed to make a metabolic characterization and identify subgroups of women with previous GDM within the first year PP. Methods: In this prospective cohort study, we collected data in gestational week 34-38, at 3 months, and 1 year PP on women with GDM who participated in a PP follow-up program in Central Region Denmark from April 2019 to December 2022. Results: In total, 1270 women were included in the program in late pregnancy. Of the 768 women participating in either the oral glucose tolerance test 3 months PP (n = 545) or the 1-year follow-up (n = 493) or both (n = 261), 608 (79.2%) were normoglycemic, 137 (17.8%) had prediabetes, 20 (2.6%) had T2DM, and 3 (.4%) had developed T1DM. More than 40% of the women gained weight in the first year PP compared with their pregestational weight. Conclusion: Our study shows that 20.8% of women with GDM who volunteered to participate in a clinical follow-up program developed prediabetes or diabetes (T1DM and T2DM) within the first year PP. The GDM diagnosis encompasses a heterogenetic group of women and a deeper characterization may provide an opportunity for a more personalized risk assessment to prevent the progression to T2DM.